multiple-myeloma

Documents about multiple-myeloma

• Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients#892971ClinicalTrials.gov
• Family Study of Lymphoproliferative Disorders#897718ClinicalTrials.gov
• A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies#911963ClinicalTrials.gov
• 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis#917534ClinicalTrials.gov
• S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma#982676ClinicalTrials.gov
• Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma#834984ClinicalTrials.gov
• Cardiovascular Comorbidities and Advanced Chronic Kidney Disease in Hospitalized Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study.#315527NCBI PubMed Central
• Supplementary Material for: Comprehensive Analysis of Disulfidptosis-Related Genes in Multiple Myeloma: Implications for Prognosis and Immune Microenvironment#370236Figshare
• Enhancing patient involvement through shared decision-making: Are we there yet in multiple myeloma? Findings from a cross-country survey.#613344NCBI PubMed Central
• FASTINA – protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.#645349NCBI PubMed Central
• NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)#651248ClinicalTrials.gov
• Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70#835457ClinicalTrials.gov
• Lapelga vs Gastrofil#891964ClinicalTrials.gov
• A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects#899314ClinicalTrials.gov
• Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool#899579ClinicalTrials.gov
• Retrospective Survey of Re-treatment With Bortezomib#900542ClinicalTrials.gov
• A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections.#975749NCBI PubMed Central
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide#861034ClinicalTrials.gov
• Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence#882624ClinicalTrials.gov
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma#980948ClinicalTrials.gov
• Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation#257729HAL (France)
• Elranatamab: A novel B-cell maturation T-cell engager#642684Europe PMC
• Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation#813673ClinicalTrials.gov
• Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS#826632ClinicalTrials.gov
• Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant#828646ClinicalTrials.gov
• Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)#831921ClinicalTrials.gov
• Rehabilitation Needs of the Malaysian Haematological Cancer Survivors#833286ClinicalTrials.gov
• Phase I Trial of VS-6766 Alone and in Combination With Everolimus#837659ClinicalTrials.gov
• Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure#861648ClinicalTrials.gov
• Risk Stratification and MRD-driven Maintenance for MM After ASCT#868448ClinicalTrials.gov
• Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer#871924ClinicalTrials.gov
• Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation#881991ClinicalTrials.gov
• Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy#887437ClinicalTrials.gov
• Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands#888073ClinicalTrials.gov
• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma#914272ClinicalTrials.gov
• Repurposing Camellia sinensis Roots and Ginkgo biloba Leaves for Multiple Myeloma via Wnt/β-Catenin-Dependent Cell Cycle Arrest and Apoptosis.#406436NCBI PubMed Central
• Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study.#645334NCBI PubMed Central
• Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies#811289ClinicalTrials.gov
• BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM#847881ClinicalTrials.gov
• Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.#888532ClinicalTrials.gov
• Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant#889955ClinicalTrials.gov
• BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT#900527ClinicalTrials.gov
• Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen#906105ClinicalTrials.gov
• Isa-Pom-Dex in Elderly/Frail Subjects With RRMM#912609ClinicalTrials.gov
• Multiple Myeloma Lesion Segmentation on Whole-Body Diffusion-Weighted Imaging via Efficient Anatomical Anticipation and Multimodal Confirmation#973767arXiv (All)
• MS-275 in Treating Patients With Hematologic Cancer#849973ClinicalTrials.gov
• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial#294456Gestión del Repositorio Documental de la Universidad de Salamanca
• Leukaemia, lymphoma, and multiple myeloma mortality after low-level exposure to ionising radiation in nuclear workers (INWORKS): updated findings from an international cohort study#161210HAL (France)
• Early Assessment of Cardiac Function After Treatment With CAR-T Cells#230421ClinicalTrials.gov
• Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation#279492ClinicalTrials.gov